← Back to headlines
Sarepta Therapeutics Stock Surges on Positive Trial Results and Analyst Upgrade
Sarepta Therapeutics (SRPT) shares skyrocketed 35% following a price target hike from Morgan Stanley and the announcement of stellar trial results for the company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
